A CRA expert was retained in an antitrust matter involving patent settlement agreements between branded and generic pharmaceutical manufacturers that involved so-called ‘reverse payments’. Plaintiffs alleged that the agreements involved a conspiracy to fix prices and allocate markets, and that this conspiracy involved an exclusionary scheme to maintain a monopoly. CRA’s expert determined that generic versions of the drug would not likely have entered earlier absent the settlement agreements, the relevant market included competing branded products, and the agreements were not anticompetitive.
Keler Marku joins CRA's Antitrust & Competition Practice
“We are pleased to welcome Keler back to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Keler is an expert in...